Literature DB >> 7047385

Inhibition of cytokine production by a tumor cell product.

E Farram, M Nelson, D S Nelson, D K Moon.   

Abstract

Supernatants from cultured mouse and human tumour cells, but not mouse or guinea-pig fibroblasts, inhibited the production of a lymphokine, macrophage chemotactic factor, by PHA-stimulated mouse spleen cells. The supernatants affected spleen cells from old, but not young, mice. They were most active if added at the start of the spleen cell culture and did not act by binding phytohaemagglutinin (PHA). The active material had an approximate molecular weight, on membrane filtration, of 1000-10,000 and could be bound to and eluted from Con A-Sepharose. Tumour supernatant factor(s) of similar molecular weight inhibited the production of interleukin 1 (lymphocyte activating factor) in response to lipopolysaccharide by stimulated thioglycollate-induced peritoneal exudate macrophages, but not by Corynebacterium parvum-activated macrophages. Similar tumour-produced material has been found to inhibit the early phase of delayed-type hypersensitivity reactions in older mice. It is suggested that this effect is due, at least in part, to inhibition of interleukin 1 production leading to inhibition of lymphokine production.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047385      PMCID: PMC1555304     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  The role of macrophages in the production of lymphokines by T and B lymphocytes.

Authors:  S M Wahl; J M Wilton; D L Rosenstreich; J J Oppenheim
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

Review 2.  The macrophage as an antineoplastic surveillance cell: biological perspectives.

Authors:  J B Hibbs; H A Chapman; J B Weinberg
Journal:  J Reticuloendothel Soc       Date:  1978-11

3.  Chemotactic response of mouse macrophages to culture fluids mitogen-stimulated spleen cells.

Authors:  M S Meltzer
Journal:  Clin Immunol Immunopathol       Date:  1976-09

4.  Suppression of tuberculin and phytohemagglutinin skin tests by large tumors in inbred mice.

Authors:  J H Wells; W A Cain; R S Wells; J R Bozalis
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

5.  Concomitant immunity to syngeneic methylcholanthrene-induced tumours in mice. Occurrence and specificity of concomitant immunity.

Authors:  R Kearney; D S Nelson
Journal:  Aust J Exp Biol Med Sci       Date:  1973-12

6.  A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration.

Authors:  W Falk; R H Goodwin; E J Leonard
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

7.  Isolation of an inhibitor of type II interferon induction from tumor ascitic fluids.

Authors:  S Matsubara; M Suzuki; M Nakamura; K Edo; N Ishida
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

8.  Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble prducts affecting macrophages.

Authors:  M Nelson; D S Nelson
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

9.  Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance.

Authors:  M C Pike; R Snyderman
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

10.  Antiinflammatory effects of murine malignant cells.

Authors:  R M Fauve; B Hevin; H Jacob; J A Gaillard; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

View more
  12 in total

1.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Suppression of both macrophage-mediated tumor cell lysis and cytolytic factor production by a factor (CIF) derived from normal embryonic fibroblasts.

Authors:  R Gallily; G E Gifford; J Loewenstein
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products.

Authors:  M Nelson; D S Nelson; G J Cianciolo; R Snyderman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Inhibition of normal rat macrophage functions by soluble tumor products. Effect of systemic treatment with bacterial immunomodulators.

Authors:  D Iannello; L Bonina; D Delfino; M C Berlinghieri; P Mastroeni
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms.

Authors:  M Nelson; D S Nelson; P B Spradbrow; V K Kuchroo; P A Jennings; G J Cianciolo; R Snyderman
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

6.  Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse.

Authors:  A W Thomson; D K Moon; D S Nelson
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

7.  Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinoma.

Authors:  M Nelson; D S Nelson; V K Kuchroo; P B Spradbrow; P A Jennings
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour.

Authors:  L C McIntosh; L M Morrice; Y Udagawa; A W Thomson
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

9.  Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide.

Authors:  M Nelson; D Nelson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.